{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:28:40Z","timestamp":1791347320120,"version":"4.3.1"},"reference-count":41,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":1648,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:p>The goal of this study was to determine the effect of<jats:italic>CYP2B6<\/jats:italic>genetic variation on the steady\u2010state pharmacokinetics of efavirenz (600 mg\/d) in TB\/HIV co\u2010infected patients receiving concomitant rifampin, a potent<jats:italic>CYP<\/jats:italic>inducer. In the 26 patients studied,<jats:italic>CYP2B6<\/jats:italic>c.516GG, GT, and TT genotype frequencies were 0.27, 0.50, and 0.23, respectively. Mean plasma efavirenz area under the curve was significantly higher in patients with<jats:italic>CYP2B6<\/jats:italic>c.516TT than in those with GT (107 vs 27.6 \u03bcg\u00b7h\/mL,<jats:italic>P<\/jats:italic>&lt; .0001) or GG genotype (107 vs 23.0 \u03bcg\u00b7h\/mL,<jats:italic>P<\/jats:italic>&lt; .0001). Apparent oral clearance (CL\/F) was significantly lower in patients with<jats:italic>CYP2B6<\/jats:italic>c.516TT than in those with GT genotype (2.1 vs 8.4 mL\/min\/kg,<jats:italic>P<\/jats:italic>&lt; 0.0001) and GG genotype (2.1 vs 9.9 mL\/min\/kg,<jats:italic>P<\/jats:italic>&lt; .0001). No differences in efavirenz exposure or CL\/F existed between patients with<jats:italic>CYP2B6<\/jats:italic>c.516GT and GG genotypes. Our results indicate that<jats:italic>CYP2B6<\/jats:italic>c.516TT genotype can be used to identify efavirenz poor metabolizers in patients co\u2010treated with rifampin.<\/jats:p>","DOI":"10.1177\/0091270008321790","type":"journal-article","created":{"date-parts":[[2008,8,26]],"date-time":"2008-08-26T19:23:00Z","timestamp":1219778580000},"page":"1032-1040","source":"Crossref","is-referenced-by-count":42,"title":["Pharmacokinetics of Efavirenz When Co\u2010administered With Rifampin in TB\/HIV Co\u2010infected Patients: Pharmacogenetic Effect of<i>CYP2B6<\/i>Variation"],"prefix":"10.1002","volume":"48","author":[{"given":"Awewura","family":"Kwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Lartey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwamena W.","family":"Sagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fafa","family":"Xexemeku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Kenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Oliver\u2010Commey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Boima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustine","family":"Sagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Boamah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Greenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Court","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_5_2_2","unstructured":"World Health Organization.Global tuberculosis control: surveillance planning financing. WHO Report2008. WHO\/HTM\/TB\/2008.393.http:www.who.inttbpublicationsglobalreport2008pdffullreport.pdf. Accessed June 23 2008."},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.9.1009"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200201040-00010"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000230521.86964.86"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/424676"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.167.4.603"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","unstructured":"World Health Organization.Scaling up antiretroviral therapy in resource\u2010limited settings: guidelines for a public health approach 2003 revision.http:www.who.int3by5publicationsenarveng.pdf. Accessed February 11 2008.","DOI":"10.1097\/00019048-200203000-00012"},{"key":"e_1_2_5_9_2","unstructured":"Centers for Disease Control and Prevention.Managing drug interactions in the treatment of HIV\u2010related tuberculosis.http:www.cdc.govtbTBHIVDrugsdefault.htm. Accessed February 11 2008."},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17141-9"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.4.421"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.32.3.348"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1211\/0022357021657"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1269"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.049601"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.8.6.547"},{"key":"e_1_2_5_17_2","unstructured":"diLulioJ RotgerM LubomirovR DecosterdL EapCB TelentiA.Genetic variation in accessory metabolic pathways is associated with extreme efavirenz exposure in individuals with impaired CYP2B6 function. Presented at: 15th Conference on Retroviruses and Opportunistic Infections;February 36 2008; Boston Mass. Abstract 133.http:www.retroconference.org2008Abstracts32236.htm. Accessed February 11 2008."},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200107000-00004"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.05.116"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100072"},{"key":"e_1_2_5_21_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.fpc.0000189797.03845.90","article-title":"Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz","volume":"16","author":"Wang J","year":"2006","journal-title":"Pharmacogenet Geonomics"},{"key":"e_1_2_5_22_2","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","author":"Haas DW","year":"2004","journal-title":"AIDS"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/01213011-200501000-00001"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.03.010"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241090-00004"},{"key":"e_1_2_5_26_2","unstructured":"Centers for Disease Control and Prevention.Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV\u2010infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors.2004.http:www.cdc.govnchstptbTBHIVDrugsPDFtbhiv.pdf. Accessed February 11 2008."},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.2174\/157016207780636588"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl399"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/01213011-200512000-00004"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0412-3"},{"key":"e_1_2_5_31_2","unstructured":"Regulatory Compliance Center.Division of AIDS table for grading severity of adult adverse experiences August 1992.http:rcc.tech\u2010res.comDAIDS20RCC20FormsToxicityTablesAdultTRPv01a.pdf. Accessed January 21 2008."},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2006.03.014"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.133306"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.124519"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.112136"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200404000-00002"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2003.22"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544080-00006"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.20180"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M212482200"},{"key":"e_1_2_5_41_2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0026-895X(24)12603-X","article-title":"Regulation of the human CYP2B6 gene by nuclear pregnane x receptor","volume":"60","author":"Goodwin B","year":"2001","journal-title":"Mol Pharmacol"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1086\/522175"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270008321790","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270008321790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T17:47:37Z","timestamp":1738345657000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270008321790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1177\/0091270008321790"],"URL":"https:\/\/doi.org\/10.1177\/0091270008321790","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}